New semaglutide pill put to the test in healthy volunteers
NCT ID NCT05784402
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This completed Phase 1 trial tested a new formulation of oral semaglutide in 264 healthy participants. The goal was to compare how much of the drug gets into the blood from the new tablet versus the current version. Participants took different doses over 21 weeks, and researchers measured drug levels to see if the new tablet works similarly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Altasciences Clinical Company, Inc
Montreal, Quebec, H3P 3P1, Canada
-
Altasciences Clinical Kansas, Inc.
Kansas City, Kansas, 66212, United States
-
Altasciences Clinical LA, Inc.
Cypress, California, 90630, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide
What this could lead to
If successful, this could lead to a new, more effective tablet form of semaglutide for conditions like diabetes or weight management.
What could go wrong
This is an early Phase 1 study in healthy people, not patients. It only measures drug levels, not whether the drug works for any disease. The new tablet may not perform better or could have unexpected side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.